LifeTech Scientific Gross Margin
The Gross Margin of LifeTech Scientific (1302.HK) as of Jul 26, 2026 is 74.40 %. In the previous year, Gross Margin was 75.28 % — a change of -1.17% (lower).
Get this data via API
Financial Data API
Gross Margin
74.40 %
YoY
-1.17%
Last updated:
Gross Margin of LifeTech Scientific is 2026 74.40 % . Gross Margin of LifeTech Scientific was 2025 75.28 % . It decreases by -1.17% lower compared to the previous year.
For LifeTech Scientific, the gross margin of 74.4% is down versus 80.8% a few years ago.
Access this data via the Eulerpool API
LifeTech Scientific Stock analysis
What does LifeTech Scientific do? LifeTech Scientific Corp is a leading company in the field of medical technology. The company was founded in 1999 in Beijing, China and has since become a global provider of medical products and solutions. LifeTech Scientific Corp has offices in the USA, Europe, Asia, and Africa and is listed on the Hong Kong Stock Exchange.
The business model of LifeTech Scientific Corp is based on innovative medical solutions and products for cardiology and other medical specialties. The company aims to improve treatment options for patients and equip doctors with the best tools and technologies to provide the best diagnosis and treatment options.
LifeTech Scientific Corp offers a wide range of products and solutions including diagnostic devices, implantable devices, surgical devices, and accessories. These products can be used in various medical specialties such as cardiology, vascular surgery, neurology, and intensive care.
Cardiology is one of the key areas of LifeTech Scientific Corp. The company offers a wide range of products focused on treating heart conditions such as coronary artery disease, heart failure, and arrhythmias. This includes implantable cardiac devices such as Implantable Cardiac Defibrillators (ICDs) and pacemakers used to treat rhythm disorders. LifeTech Scientific Corp's devices are very advanced and provide patients with an excellent quality of life.
In addition to cardiology, LifeTech Scientific Corp also offers devices and solutions for other medical specialties. In the field of neurology, for example, the company provides devices for monitoring brain activity and treating epilepsy. In vascular surgery, LifeTech Scientific Corp offers devices for diagnosing and treating aneurysms and narrowing of blood vessels. In intensive care, the company provides devices for ventilation and patient monitoring.
The history of LifeTech Scientific Corp is characterized by continuous growth and the development of new products and solutions. In recent years, the company has built strategic partnerships with leading medical institutions and research facilities around the world to advance the development of new technologies and products.
Overall, LifeTech Scientific Corp is now one of the leading companies in the field of medical technology, offering innovative solutions for a range of medical specialties. The company is committed to improving patients' quality of life and providing doctors with the best tools and technologies to ensure the best possible treatment. LifeTech Scientific is one of the most popular companies on Eulerpool.
Frequently Asked Questions about LifeTech Scientific stock
Gross Margin of LifeTech Scientific is 74.40 % in 2026.
Access this data via the Eulerpool API
Margins — LifeTech Scientific
All Key Metrics — LifeTech Scientific
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth